These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18716419)

  • 1. Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience.
    Rey PM; Villavicencio H
    Oncology; 2008; 74(3-4):245-6. PubMed ID: 18716419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
    Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
    J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
    Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
    Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib for the treatment of advanced renal cell carcinoma.
    Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
    Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib.
    Hahn O; Stadler W
    Curr Opin Oncol; 2006 Nov; 18(6):615-21. PubMed ID: 16988583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
    Procopio G; Verzoni E; Gevorgyan A; Mancin M; Pusceddu S; Catena L; Platania M; Guadalupi V; Martinetti A; Bajetta E
    Oncology; 2007; 73(3-4):204-9. PubMed ID: 18418013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
    Stadler WM; Figlin RA; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; George JR; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Bukowski RM;
    Cancer; 2010 Mar; 116(5):1272-80. PubMed ID: 20082451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib for the management of advanced renal cell carcinoma.
    Escudier B
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):825-36. PubMed ID: 21707277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib in renal cell carcinoma.
    Flaherty KT
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):747s-752s. PubMed ID: 17255304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
    Naito S; Tsukamoto T; Murai M; Fukino K; Akaza H
    BJU Int; 2011 Dec; 108(11):1813-9. PubMed ID: 21481133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy.
    Amin C; Wallen E; Pruthi RS; Calvo BF; Godley PA; Rathmell WK
    Urology; 2008 Oct; 72(4):864-8. PubMed ID: 18684493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
    Wood LS; Manchen B
    Clin J Oncol Nurs; 2007 Oct; 11(5):649-56. PubMed ID: 17962173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib: delivering a targeted drug to the right targets.
    Flaherty KT
    Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib: new drug. Second-line treatment of kidney cancer: better evaluated than sunitinib.
    Prescrire Int; 2007 Aug; 16(90):141-3. PubMed ID: 17724834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center.
    Kennoki T; Kondo T; Kimata N; Murakami J; Ishimori I; Nakazawa H; Hashimoto Y; Kobayashi H; Iizuka J; Takagi T; Yoshida K; Tanabe K
    Jpn J Clin Oncol; 2011 May; 41(5):647-55. PubMed ID: 21367805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
    Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A
    BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
    Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
    J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
    Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
    Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
    Eng FC; Easson AM; Szentgyorgyi E; Knox JJ
    Eur J Surg Oncol; 2009 Feb; 35(2):219-21. PubMed ID: 17976949
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
    Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP
    J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.